Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ranibizumab versus sham for center-involving diabetic macular edema
2005-000487-11Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2005
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ranibizumab in diabetic macular edema (DME) (3 arms), sponsored by Novartis. Primary endpoint: Change in macular edema from baseline to Month 6. Started Aug 2005; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2005-000487-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000487-11.